How I treat How I treat relapsed childhood acute lymphoblastic leukemia
نویسندگان
چکیده
The most common cause of treatment failure in childhood acute lymphoblastic leukemia (ALL) remains relapse, occurring in 15%-20% of patients. Survival of relapsed patients can be predicted by site of relapse, length of first complete remission, and immunophenotype of relapsed ALL. BM and early relapse (< 30 months from diagnosis), as well as T-ALL, are associated with worse prognosis than isolated extramedullary or late relapse (> 30 months from diagnosis). In addition, persistence of minimal residual disease (MRD) at the end of induction or consolidation therapy predicts poor outcome because children with detectable MRD are more likely to relapse than those in molecular remission, even after allogeneic hematopoietic stem cell transplantation. We offer hematopoietic stem cell transplantation to any child with high-risk features because these patients are virtually incurable with chemotherapy alone. By contrast, we treat children with first late BM relapse of B-cell precursor ALL and good clearance of MRD with a chemotherapy approach. We use both systemic and local treatment for extramedullary relapse, mainly represented by radiotherapy and, in case of testicular involvement, by orchiectomy. Innovative approaches, including new agents or strategies of immunotherapy, are under investigation in trials enrolling patients with resistant or more advanced disease. (Blood. 2012;120(14):2807-2816)
منابع مشابه
How I treat relapsed childhood acute lymphoblastic leukemia Short Title: Treatment of relapsed ALL in childhood
متن کامل
How I treat relapsed childhood acute lymphoblastic leukemia.
The most common cause of treatment failure in childhood acute lymphoblastic leukemia (ALL) remains relapse, occurring in ~ 15%-20% of patients. Survival of relapsed patients can be predicted by site of relapse, length of first complete remission, and immunophenotype of relapsed ALL. BM and early relapse (< 30 months from diagnosis), as well as T-ALL, are associated with worse prognosis than iso...
متن کاملTreatment Costs for Pediatrics Acute Lymphoblastic Leukemia; Comparing Clinical Expenditures in Developed and Developing Countries: a Review Article
Background Pediatric acute lymphoblastic leukemia (ALL) is the most common, yet curable childhood malignancy within the pediatric cancers; but in most developed and developing countries cost of cancer treatment in children with ALL is high. So, we specified the range of expenses for the treatment of pediatric cancer and compared the results in devel...
متن کاملHow I Treat How I treat older patients with ALL
3104. 60. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensiveconsolidation for adults with acute lymphoblasticleukemia: cancer and leukemia group B study8811. Blood. 1995;85(8):2025-2037. 61. van Schie RM, Brüggemann RJ, HoogerbruggePM, te Loo DM. Effect of azole antifungal therapyon vincristine toxicity in childhood acutelymp...
متن کاملHow I treat How I treat acute lymphocytic leukemia in adults
The treatment of newly diagnosed acute lymphocytic leukemia (ALL) in adults remains unsatisfactory. Not withstanding the outstanding progress in curing childhood ALL, only approximately one third of adults younger than 60 years can be cured, and the overall published survival curves have not changed significantly during the past 15 years. Recent therapeutic advances in allogeneic transplantatio...
متن کامل